Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets

Rory D. de Vries\textsuperscript{1@}, Katharina S. Schmitz\textsuperscript{1@}, Francesca T. Bovier\textsuperscript{2,3,4@}, Danny Noack\textsuperscript{1}, Bart L. Haagmans\textsuperscript{1}, Sudipta Biswas\textsuperscript{5}, Barry Rockx\textsuperscript{1}, Samuel H. Gellman\textsuperscript{6}, Christopher A. Alabi\textsuperscript{*5}, Rik L. de Swart\textsuperscript{*1}, Anne Moscona\textsuperscript{2,3,7,8}, Matteo Porotto\textsuperscript{*2,3,4}

\textsuperscript{1} Department Viroscience, Erasmus MC, Rotterdam, the Netherlands
\textsuperscript{2} Department of Pediatrics, Columbia University Medical Center, New York, NY, USA
\textsuperscript{3} Center for Host–Pathogen Interaction, Columbia University Medical Center, New York, NY, USA
\textsuperscript{4} Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, 81100 Caserta, Italy
\textsuperscript{5} Robert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, New York, USA.
\textsuperscript{6} Department of Chemistry, University of Wisconsin, Madison, WI, USA
\textsuperscript{7} Department of Microbiology & Immunology, Columbia University Medical Center, New York, NY, USA
\textsuperscript{8} Department of Physiology & Cellular Biophysics, Columbia University Medical Center, New York, NY, USA

@ Authors contributed equally

* Corresponding authors

Contacts details:
- Christopher A. Alabi: caa238@cornell.edu
- Rik L. de Swart: r.deswart@erasmusmc.nl
- Anne Moscona: am939@cumc.columbia.edu
- Matteo Porotto: mp3509@cumc.columbia.edu

One-sentence summary: A dimeric form of a SARS-CoV-2-derived lipopeptide is a potent inhibitor of fusion and infection \textit{in vitro} and transmission \textit{in vivo}. 
Abstract

Containment of the COVID-19 pandemic requires reducing viral transmission. SARS-CoV-2 infection is initiated by membrane fusion between the viral and host cell membranes, mediated by the viral spike protein. We have designed a dimeric lipopeptide fusion inhibitor that blocks this critical first step of infection for emerging coronaviruses and document that it completely prevents SARS-CoV-2 infection in ferrets. Daily intranasal administration to ferrets completely prevented SARS-CoV-2 direct-contact transmission during 24-hour co-housing with infected animals, under stringent conditions that resulted in infection of 100% of untreated animals. These lipopeptides are highly stable and non-toxic and thus readily translate into a safe and effective intranasal prophylactic approach to reduce transmission of SARS-CoV-2.
Main text

Infection by SARS-CoV-2 requires membrane fusion between the viral envelope and the host cell membrane, at either the cell surface or the endosomal membrane. The fusion process is mediated by the viral envelope spike glycoprotein, S. Upon viral attachment or uptake, host factors trigger large-scale conformational rearrangements in S, including a refolding step that leads directly to membrane fusion and viral entry (1-6). Peptides corresponding to the highly conserved heptad repeat (HR) domain at the C-terminus of the S protein (HRC peptides) may prevent this refolding and inhibit fusion, thereby preventing infection (7-12) (Fig. 1a-c). The HRC peptides form six-helix bundle (6HB)-like assemblies with the extended intermediate form of the S protein trimer, thereby disrupting the structural rearrangement of S that drives membrane fusion (7).

We have previously demonstrated that lipid conjugation of HRC-derived inhibitory peptides markedly increases antiviral potency and in vivo half-life (13-16), and used this strategy to create entry inhibitors for prophylaxis and/or treatment of human parainfluenza virus type 3, measles virus, and Nipah virus infection (14, 15, 17-20). Both dimerization and peptide integration into cell membranes proved key to ensure respiratory tract protection and prevent systemic lipopeptide dissemination (16, 18). The lipid-conjugated peptides administered intranasally to animals reached high concentrations both in the upper and lower respiratory tract, and the specific nature of the lipid can be designed to modulate the extent of transit from the lung to the systemic circulation and organs (18-22). Lipid conjugation also enabled activity against viruses that do not fuse until they have been taken up via endocytosis (23). Here, we show that a dimeric form of a SARS-CoV-2 S-specific lipopeptide is a potent inhibitor of fusion mediated by the SARS-CoV-2 S protein, prevents viral entry, and, when administered intranasally, completely prevents direct-contact transmission of SARS-CoV-2 in ferrets. We propose this compound as a candidate antiviral, to be administered by inhalation or intranasal spray, for pre-exposure or early post-exposure prophylaxis for SARS-CoV-2 transmission in humans.
To improve the antiviral potency of the previously assessed SARS-CoV-2 HRC-lipopeptide fusion inhibitor (7), we compared monomeric and dimeric derivatives of the SARS-CoV-2 S-derived HRC-peptide (Fig. 1d). Initial functional evaluation of the SARS-CoV-2 HRC lipopeptides was conducted with a cell-cell fusion assay based on β-galactosidase (β-gal) complementation that we adapted for assessment of SARS-CoV-2 S-mediated fusion. For this assay, cells expressing human angiotensin-converting enzyme 2 (hACE2) and the N-terminal fragment of β-gal were mixed with cells expressing the SARS-CoV-2 S protein and the C-terminal fragment of β-gal. When fusion mediated by S occurs, the two fragments of β-gal combine to generate a catalytically active species, and fusion is detected via the luminescence that results from substrate processing by β-gal. This assay format allows the assessment of potential SARS-CoV-2 S-mediated membrane fusion inhibitors without the use of infectious virus. The assay measures an inhibitor’s ability to block fusion of S-bearing cells with receptor-bearing target cells and is predictive of in vivo antiviral activity (14).

Fig. 1d shows the antiviral potency of two monomeric and two dimeric SARS-CoV-2 S-derived 36-amino acid (Fig. 1b) HRC-peptides, without (SARS_{HRC} and [SARS_{HRC}-PEG_{4}]_2) or with (SARS_{HRC}-PEG_{4}-chol and [SARS_{HRC}-PEG_{4}]_2-chol) appended cholesterol, in cell-cell fusion assays. The percentage inhibition corresponds to the extent of luminescence signal suppression observed in the absence of any inhibitor (i.e., 0% inhibition corresponds to maximum luminescence signal). Dimerization increased the peptide potency (see SARS_{HRC} vs. [SARS_{HRC}-PEG_{4}]_2 in Fig. 1d). The dimeric form of HRC lipopeptide was also more potent than its monomeric lipopeptide counterpart (SARS_{HRC}-PEG_{4}-chol IC_{50} ~10 nM and [SARS_{HRC}-PEG_{4}]_2-chol IC_{50} ~3 nM, (Two-way ANOVA, p<0.0001)). This dimeric cholesterol-conjugated peptide ([SARS_{HRC}-PEG_{4}]_2-chol; red line in Fig. 1d) is the most potent lipopeptide against SARS-CoV-2 that has been identified thus far. A lipopeptide based on the human parainfluenza virus type 3 (HPIV3) F protein HRC domain, used as a negative control, did not inhibit fusion at any
concentration tested (Fig. S1). A cellular toxicity (MTT) assay was performed in parallel with this experiment to evaluate the potential toxicity of each lipopeptide (Fig. S2). Toxicity for each of the lipopeptides in this assay was minimal, even at the highest concentrations tested (<20% at 100 µM). No toxicity was observed for the dimeric SARS-CoV-2 lipopeptide at its IC$_{90}$ entry inhibitory concentration (~350 nM).

Despite the overall stability of the SARS-CoV-2 genome, variants with mutations in S have spread globally (24-32). These mutations in S altered infectivity of cells (e.g., D614G (24)) or were located in the putative target domain of the HRC peptide (e.g., S943P). To determine the potency of the [SARS$_{HRC}$-PEG$_4$]$_2$-chol peptide for a range of variant SARS-CoV-2 viruses, we examined fusion inhibition mediated by each of these emerging S protein mutants. In addition, to assess the potential for broad-spectrum activity we assessed potency against the S of SARS-CoV and MERS-CoV (using dipeptidyl peptidase 4 (DPP4) receptor-bearing cells as the target for the latter). Fig. 1e shows the IC$_{50}$ and IC$_{90}$ of [SARS$_{HRC}$-PEG$_4$]$_2$-chol for inhibition of fusion by the S mutants and in addition, for SARS-CoV S and MERS-CoV S. The [SARS$_{HRC}$-PEG$_4$]$_2$-chol lipopeptide inhibited all SARS-CoV-2 strains with S mutations at comparable potency and showed considerable potency against both SARS-CoV and MERS-CoV.

The lead peptide, [SARS$_{HRC}$-PEG$_4$]$_2$-chol, was subsequently assessed for its ability to block entry of live SARS-CoV-2 in VeroE6 and VeroE6 cells overexpressing the protease TMPRSS2 (33), one of the host factors thought to facilitate viral entry at the cell membrane (2). The TMPRSS2-expressing cells accurately represent the entry route in airway cells, an important feature highlighted by the failure of chloroquine to inhibit infection in TMPRSS2-expressing Vero cells and in human lung cells (34). The [SARS$_{HRC}$-PEG$_4$]$_2$-chol peptide was dissolved in an aqueous buffer containing 2% dimethylsulfoxide (DMSO), was incubated with cells for 1 hr at 37 °C, after which a fixed concentration of SARS-CoV-2
was added. After 8 hrs at 37 °C, fusion events were quantified by SARS-CoV-2 nucleoprotein (NP) staining. The [SARS_{HRC}-PEG₄]₂-chol peptide inhibited live virus entry with an IC₅₀ ~300 nM in cells not overexpressing TMPRSS2 and ~5 nM in VeroE6-TMPRSS2, with an IC₉₀ ~1 uM in both cell types (Fig. 2a). In addition, we assessed the efficacy of the [SARS_{HRC}-PEG₄]₂-chol peptide dissolved in a sucrose solution instead of DMSO, which would strengthen translational potential for human use. [SARS_{HRC}-PEG₄]₂-chol peptide retained its potency in this formulation, with an IC₅₀ ~300 nM in cells not overexpressing TMPRSS2 and ~5 nM in VeroE6-TMPRSS2 (Fig. 2b). The efficacy data are summarized in Fig. 2c.

Ferrets are an ideal model for assessing respiratory virus transmission, either by direct contact or by aerosol transmission (35-40). Mustelids are highly susceptible to infection with SARS-CoV-2, as also illustrated by frequent COVID-19 outbreaks at mink farms (41). Direct contact transmission of SARS-CoV in ferrets was demonstrated in 2003 (42), and both direct contact and airborne transmission have recently been shown in ferrets for SARS-CoV-2 (36, 43, 44). Direct contact transmission in the ferret model is highly reproducible (100% transmission from donor to acceptor animals), but ferrets display limited clinical signs. After infection via direct inoculation or transmission, SARS-CoV-2 can readily be detected in and isolated from the throat and nose, and viral replication leads to seroconversion.

To assess the efficacy of [SARS_{HRC}-PEG₄]₂-chol in preventing SARS-CoV-2 transmission, naive ferrets were treated prophylactically with the lipopeptide before being co-housed with SARS-CoV-2 infected ferrets. In this setup, transmission via multiple routes can theoretically occur (aerosol, orofecal, and scratching or biting during play or fight), and ferrets are continuously exposed to infectious virus during the period of co-housing, providing a stringent test for antiviral efficacy. The study design is shown in Fig. 3a. Three donor ferrets (grey in diagram) were inoculated intranasally with 5.4 x 10⁵ TCID₅₀ SARS-CoV-2 on day 0. Twelve recipient ferrets housed separately were treated by nose drops with a mock
preparation (red) or [SARS\textsubscript{HRC}-PEG\textsubscript{4}]\textsubscript{2}-chol peptide (green) on 1- and 2-days post-inoculation (DPI) of the donor animals. The [SARS\textsubscript{HRC}-PEG\textsubscript{4}]\textsubscript{2}-chol peptides for intranasal administration were dissolved to a concentration of 6 mg/mL in an aqueous buffer containing 2% DMSO, administering a final dose of 2.7 mg/kg to ferrets (450 uL, equally divided over both nostrils). Six hours after the second treatment on 2 DPI, one infected donor ferret was co-housed with four naive recipient ferrets (two mock-treated, two peptide-treated). The experiment was performed in three separate, negatively pressurized HEPA-filtered ABSL3-isolator cages. After a 24-hour transmission period, co-housing was stopped and donor, mock-treated and peptide-treated ferrets were housed as separate groups. Additional [SARS\textsubscript{HRC}-PEG\textsubscript{4}]\textsubscript{2}-chol peptide treatments were given to recipient animals on 3 and 4 DPI. Peptide stocks and working dilutions had similar IC\textsubscript{50} s, confirming that peptide-treated ferrets were always dosed with comparable amounts (Fig. S3a and 3b).

Throat and nose swabs were collected from ferrets daily for the first week, and additionally on 14 and 21 DPI, for assessment of viral replication. Small volume blood samples were collected on 0, 7, 14, and 21 DPI for assessing the presence of neutralizing antibodies in serum. Fig. 3b and 3c shows the viral loads (detection of viral genomes via RT-qPCR) for directly inoculated donor animals (grey), mock-treated recipient animals (red) and lipopeptide-treated recipient animals (green). All directly inoculated donor ferrets were productively infected, as shown by SARS-CoV-2 genome detection in throat and nose swabs, and efficiently and reproducibly transmitted the virus to all mock-treated acceptor ferrets (Fig. 3b and 3c, red curves). Notably, productive SARS-CoV-2 infection was not detected in the throat or nose of any of the peptide-treated recipient animals (Fig. 3b and 3c, green curves). A slight rise in viral loads in samples collected at 3DPI was detected, at the end of the co-housing, confirming that peptide-treated animals were exposed to SARS-CoV-2. Strikingly, from 4 DPI onwards, there was a clear treatment effect in which the [SARS\textsubscript{HRC}-PEG\textsubscript{4}]\textsubscript{2}-chol peptide protected 6/6 ferrets from transmission and productive infection. Donor ferrets and 6/6 mock-treated recipient animals seroconverted on 21 DPI.
None of the peptide-treated animals seroconverted, demonstrating that in-host virus replication was completely blocked by [SARS_{HRC-PEG4}]_{2}-chol (Fig. 4). None of the animals showed clinical signs as a result of infection or treatment over the course of the experiment, and body weights remained stable (Fig. S4).

Based on the in vitro and in vivo results shown here, we expect that prophylactic intranasal administration of the [SARS_{HRC-PEG4}]_{2}-chol peptide prevents transmission from infected to uninfected individuals, even during a 24-hour period of intense direct contact. In vitro data suggest that this lipopeptide will be effective against emerging variants with mutations in S and possibly against other coronaviruses. This efficacy can be readily assessed in real time and adjustments made if needed.

Parallel approaches to prevent transmission that target ACE2 or the interaction between S and ACE2 have also shown promise in vitro (e.g. the “miniprotein” approach recently reported by Cao et al (45)). In distinction to various antibody or nanobody products (46) the [SARS_{HRC-PEG4}]_{2}-chol peptide is inexpensive to produce, has a long shelf life, and does not require refrigeration. Moreover, this is the first compound to convincingly prevent SARS-CoV-2 transmission in a relevant animal model. We envision the use of fusion inhibitory lipopeptides as complementary to other pandemic mitigation strategies. In addition to the nasal drop administration for the [SARS_{HRC-PEG4}]_{2}-chol peptide, other routes that would be equally or more acceptable to humans, for example inhalation devices, are being explored. This HRC lipopeptide fusion inhibitor is feasible for advancement to human use and should readily translate into a safe and effective nasal spray or inhalation administered fusion inhibitor for anti-SARS-CoV-2 prophylaxis, thus supporting containment of the current COVID-19 pandemic.
References

1. F. Li, Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annu Rev Virol* **3**, 237-261 (2016).
2. M. Hoffmann *et al.*, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell.*, (2020).
3. Y. Wan, J. Shang, R. Graham, R. S. Baric, F. Li, Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J Virol* **94**, (2020).
4. P. Zhou *et al.*, A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature.*, (2020).
5. B. J. Bosch, R. van der Zee, C. A. de Haan, P. J. Rottier, The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. *J Virol* **77**, 8801-8811 (2003).
6. A. C. Walls *et al.*, Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. *Proc Natl Acad Sci U S A* **114**, 11157-11162 (2017).
7. V. K. Outlaw *et al.*, Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. *mBio* **11**, (2020).
8. S. Xia, Q. Wang, S. W. Liu, L. Lu, S. B. Jiang, [Development of peptidic MERS-CoV entry inhibitors]. *Yao Xue Xue Bao* **50**, 1513-1519 (2015).
9. S. Xia *et al.*, A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. *Sci Adv* **5**, eaav4580 (2019).
10. S. Xia *et al.*, Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Res* **30**, 343-355 (2020).
11. Y. Zhu, D. Yu, H. Yan, H. Chong, Y. He, Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. *J Virol* **94**, (2020).
12. X. Wang *et al.*, Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. *Int J Mol Sci* **21**, (2020).
13. M. Porotto *et al.*, Viral entry inhibitors targeted to the membrane site of action. *J Virol* **84**, 6760-6768 (2010).
14. M. Porotto *et al.*, Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. *PLoS Pathog* **6**, e1001168 (2010).
15. A. Pessi *et al.*, A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity. *PLoS One* **7**, e36833 (2012).
16. J. C. Welsch *et al.*, Fatal measles virus infection prevented by brain-penetrant fusion inhibitors. *J Virol* **87**, 13785-13794 (2013).
17. V. K. Outlaw *et al.*, Dual Inhibition of Human Parainfluenza Type 3 and Respiratory Syncytial Virus Infectivity with a Single Agent. *J Am Chem Soc* **141**, 12648-12656 (2019).
18. T. N. Figueira *et al.*, Structure-Stability-Function Mechanistic Links in the Anti-Measles Virus Action of Tocopherol-Derivatized Peptide Nanoparticles. *ACS Nano* **12**, 9855-9865 (2018).
19. T. N. Figueira *et al.*, Effective in Vivo Targeting of Influenza Virus through a Cell-Penetrating/Fusion Inhibitor Tandem Peptide Anchored to the Plasma Membrane. *Bioconjug Chem* **29**, 3362-3376 (2018).
20. C. Mathieu *et al.*, Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides. *Sci Rep* **7**, 43610 (2017).
21. T. N. Figueira *et al.*, In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence. *J Virol* **91**, (2017).
22. T. N. Figueira et al., Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance. Sci Rep 7, 45647 (2017).
23. K. K. Lee et al., Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus. J Biol Chem 286, 42141-42149 (2011).
24. L. Zhang et al., The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv, (2020).
25. Z. Daniloski, X. Guo, N. E. Sanjana, The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types. bioRxiv, (2020).
26. Y. N. Gong et al., SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East. Emerg Microbes Infect, 1-37 (2020).
27. A. Maitra et al., Mutations in SARS-CoV-2 viral RNA identified in Eastern India: Possible implications for the ongoing outbreak in India and impact on viral structure and host susceptibility. J Biosci 45, (2020).
28. I. Karacan et al., The origin of SARS-CoV-2 in Istanbul: Sequencing findings from the epicenter of the pandemic in Turkey. North Clin Istamb 7, 203-209 (2020).
29. N. K. Biswas, P. P. Majumder, Analysis of RNA sequences of 3636 SARS-CoV-2 collected from 55 countries reveals selective sweep of one virus type. Indian J Med Res, (2020).
30. M. Eaaswarkhanth, A. Al Madhoun, F. Al-Mulla, Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality? Int J Infect Dis 96, 459-460 (2020).
31. S. J. Kim, V. G. Nguyen, Y. H. Park, B. K. Park, H. C. Chung, A Novel Synonymous Mutation of SARS-CoV-2: Is This Possible to Affect Their Antigenicity and Immunogenicity? Vaccines (Basel) 8, (2020).
32. T. Koyama, D. Weeraratne, J. L. Snowdon, L. Parida, Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment. Pathogens 9, (2020).
33. A. Z. Mykytyn et al., The SARS-CoV-2 multibasic cleavage site facilitates early serine protease-mediated entry into organoid-derived human airway cells. bioRxiv, 2020.2009.2007.286120 (2020).
34. M. Hoffmann et al., Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature 585, 588-590 (2020).
35. C. Munoz-Fontela et al., Animal models for COVID-19. Nature, (2020).
36. M. Richard et al., SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat Commun 11, 3496 (2020).
37. V. J. Munster et al., Practical considerations for high-throughput influenza A virus surveillance studies of wild birds by use of molecular diagnostic tests. J Clin Microbiol 47, 666-673 (2009).
38. V. J. Munster, R. A. Fouchier, Avian influenza virus: of virus and bird ecology. Vaccine 27, 6340-6344 (2009).
39. S. Herfst et al., Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336, 1534-1541 (2012).
40. R. D. de Vries et al., Delineating morbillivirus entry, dissemination and airborne transmission by studying in vivo competition of multicolor canine distemper viruses in ferrets. PLoS Pathog 13, e1006371 (2017).
41. R. J. Molenaar et al., Clinical and Pathological Findings in SARS-CoV-2 Disease Outbreaks in Farmed Mink (Neovison vison). Vet Pathol 57, 653-657 (2020).
42. B. E. Martina et al., Virology: SARS virus infection of cats and ferrets. Nature 425, 915 (2003).
43. S. J. Park et al., Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. MBio 11, (2020).
44. Y. I. Kim et al., Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. *Cell Host Microbe* **27**, 704-709 e702 (2020).

45. L. Cao et al., De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. *Science* **370**, 426-431 (2020).

46. M. Schoof et al., An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation. *bioRxiv*, (2020).
Acknowledgements

We thank Mart Lamers, Sander Herfst, Elwin Verveer, Anna Mykytyn and Marion Koopmans for their contributions to this study. **Funding:** This work was supported by funding from the National Institutes of Health (AI146980, AI121349, and NS091263 to MP, AI114736 to AM), the Sharon Golub Fund at Columbia University Medical Center, and a Harrington Discovery Institute COVID-19 Award to AM.

**Author contributions:** conceptualization RDdV, SHG, CAA, RLdS, AM, MP; formal analysis RDdV, FTB, CAA, KSS, MP; funding acquisition BLH, RLdS, AM, MP; investigation RDdV, FTB, KSS, DN, SHG, CAA, RLdS, MP; resources BLH, BR, CAA, RLdS, AM, MP; supervision RLdS, CAA, AM, MP; visualization RDdV, KS, AM, MP; writing – original draft RDdV. RLdS, AM, MP; final version: all co-authors provided feedback to the final draft. **Competing interest:** RDdV, FTB, RLdS, AM and MP are listed as inventors on a provisional patent application covering findings reported in this manuscript. **Data and materials availability:** All data is available in the manuscript or the supplementary materials.
Figure 1: Peptide-lipid conjugates that inhibit SARS-CoV-2 spike (S)-mediated fusion. (A) The functional domains of SARS-CoV-2 S protein: receptor-binding domain (RBD) and heptad repeats (HRN and HRC) are indicated. (B) Sequence of the peptides that derive from the HRC domain of SARS-CoV-2 S. (C) Monomeric and dimeric forms of lipid tagged SARS-CoV-2 inhibitory peptides that were assessed in cell-cell fusion assays. (D) Cell-cell fusion assays with different inhibitory peptides. The percentage inhibition is shown for four different peptides used at increasing concentrations. Inhibitory concentrations 50% and 90% were calculated (dotted lines). Percent inhibition was calculated as the ratio of relative luminescence units in the presence of a specific concentration of inhibitor and the relative luminescence units in the absence of inhibitor and corrected for background luminescence. Data are means ± standard deviation (SD) from three separate experiments. The difference between the results for [SARS_{HRC}-PEG_4]-chol and SARS_{HRC}-PEG_4-chol lipopeptides are significant (Two-way ANOVA, **** p<0.0001). (E) Fusion inhibitory activity of [SARS_{HRC}-PEG_4]-chol peptide against SARS-CoV-2 S variants, MERS-CoV-2 S, and SARS-CoV S. Data are means ± standard deviation (SD) from three separate experiments.
Figure 2. Inhibition of live SARS-CoV-2 entry by [SARS-CoV-2-HRC-PEG₄]₂-chol peptide. The percentage inhibition of infection is shown on VeroE6 and VeroE6-TMPRSS2 cells with increasing concentrations of [SARS-CoV-2-HRC-PEG₄]₂-chol. A DMSO-diluted stock (A, as used in ferrets) and sucrose-diluted stock (B, potential formulation for human use) were tested side-by-side. Inhibitory concentrations 50% and 90% were calculated (dotted lines). (C) Inhibitory concentrations 50% and 90% of [SARS_HRC-PEG₄]₂-chol in live SARS-CoV-2 viral infection assays in VeroE6 cells with or without TMPRSS2 protease overexpression.
Figure 3. [SARS\textsubscript{HRC-PEG_4}]\textsubscript{-chol} prevents SARS-CoV-2 transmission \textit{in vivo}. (a) Experimental design. (b) Viral loads detected in throat and nose swabs via RT-PCR. Viral loads are displayed as 40-Ct. Donor animals shown in grey, mock-treated animals in red, peptide-treated animals in green. 3/3 donor animals, 6/6 mock-treated animals and 0/6 lipopeptide-treated animals were productively infected. Symbols correspond to individual animals and are consistent throughout figures.
Figure 4. [SARS_{HRC-PEG4}]_{2}-chol-treated animals do not seroconvert. Presence of neutralizing antibodies was determined in a live virus neutralization assay. Virus neutralizing antibodies are displayed as endpoint serum dilution factor to block SARS-CoV-2 replication. Donor animals shown in grey, mock-treated animals in red, peptide-treated animals in green. 3/3 donor animals, 6/6 mock-treated animals and 0/6 lipopeptide-treated animals seroconverted. Symbols correspond to individual animals and are consistent throughout figures.
Supplementary Materials

List of Supplementary Materials:

Materials and Methods

Figure S1 – S5

Materials and Methods

Ethics statement. Influenza virus, SARS-CoV-2 and Aleutian Disease Virus seronegative female ferrets (Mustela putorius furo), weighing 900-1200g, were obtained from a commercial breeder (Triple F Farms, PA, USA). Animals were housed and experiments were performed in compliance with the Dutch legislation for the protection of animals used for scientific purposes (2014, implementing EU Directive 2010/63). Research was conducted under a project license from the Dutch competent authority (license number AVD1010020174312) and the study protocol was approved by the institutional Animal Welfare Body (Erasmus MC permit number 17-4312-07). Animal welfare was monitored on a daily basis.

Lipopeptide synthesis. The peptide (SARS\textsubscript{HRC}) corresponding to residues 1168–1203 of SARS-CoV-2 S with a C-terminal -GSGSGC spacer sequence was prepared by solid phase peptide synthesis (SPPS). The SARS\textsubscript{HRC} peptide was acetylated at the N-terminus and amidated at the C-terminus. The crude peptide was purified by reversed-phase HPLC chromatography and characterization by MALDI-TOF MS. The SARS\textsubscript{HRC}-PEG\textsubscript{4}-chol, [SARS\textsubscript{HRC}]\textsubscript{2}-PEG\textsubscript{11}, and [SARS\textsubscript{HRC}-PEG\textsubscript{4}]\textsubscript{2}-chol were synthesized via chemoselective thiol- Michael addition reactions between the terminal thiol group on the peptide cysteine residue and maleimide functional PEG linkers or PEG-cholesterol linkers as previously
described (1). HPLC purification and lyophilization yielded the peptide-lipid conjugates as white powders. The identity of the conjugates was verified by MALDI-TOF MS (Fig. S5).

Dissolving [SARS\textsubscript{HRC}-PEG\textsubscript{4}]\textsubscript{2}-chol for use in experiments. [SARS\textsubscript{HRC}-PEG\textsubscript{4}]\textsubscript{2}-chol was supplied as a white powder in aliquots of 10 mg. For \textit{in vitro} experiments with live virus and \textit{in vivo} experiments in ferrets, 10 mg of [SARS\textsubscript{HRC}-PEG\textsubscript{4}]\textsubscript{2}-chol was dissolved in 33.3 ul DMSO, which was subsequently added to 1632.7 ul de-ionized H\textsubscript{2}O. This yielded a final aqueous solution of lipopeptide dissolved at a concentration of 6 mg/mL containing 2% DMSO. To obtain peptide dissolved in aqueous solution without DMSO, 100 mg/ml of the [SARS\textsubscript{HRC}-PEG\textsubscript{4}]\textsubscript{2}-chol peptide in DMSO (10 mg of peptide in 100 ul of DMSO) and 1 mg/ml of sucrose in sterile water were prepared. 10 ul of the peptide solution (1mg) was added to 100µl of sucrose (0.1 mg). Lyophilisation of the peptide solution (DMSO + sucrose) was performed over-night and dry powder was resuspended in 50µl of sterile water to a final concentration is 20 mg/ml in water without any DMSO.

Cells. Human kidney Epithelial (HEK) 293T and Vero (African green monkey kidney) cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen; Thermo Fisher Scientific) supplemented with 10% foetal bovine serum (FBS) and antibiotics in 5% CO\textsubscript{2} at 37°C. VeroE6 (ATCC CRL-1586) and VeroE6-TMPRSS2 cells were grown in DMEM (Gibco) with 10% FBS, 2 mM L-glutamine (Gibco), 10 mM Hepes (Lonza), 1.5 mg/ml sodium bicarbonate (NaHCO\textsubscript{3}, Lonza), penicillin (10,000 IU/mL) and streptomycin (10,000 IU/mL)(2).

HAE cultures. The EpiAirway AIR-100 system (MatTek Corporation) consists of normal human-derived tracheal/bronchial epithelial cells that have been cultured to form a pseudostratified, highly
differentiated mucociliary epithelium closely resembling that of epithelial tissue in vivo. Cultures were transferred to six-well plates containing 1.0 ml medium per well (basolateral feeding, with the apical surface remaining exposed to air) and acclimated at 37°C in 5% CO2 for 24h prior to experimentation (3).

**Plasmids.** The cDNAs coding for hACE2 fused to the fluorescent protein Venus, dipeptidyl peptidase 4 (DPP4) fused to the fluorescent protein Venus, SARS-CoV-2 S, SARS-CoV S, and MERS-S (codon optimized for mammalian expression) were cloned in a modified version of the pCAGGS (with puromycin resistance for selection).

**β-Gal complementation-based fusion assay.** We previously adapted a fusion assay based on alpha complementation of β-galactosidase (β-Gal)(4). In this assay, hACE2 receptor-bearing cells (or dipeptidyl peptidase 4 (DPP4) receptor-bearing cells for MERS-CoV-2 experiments) expressing the omega peptide of β-Gal are mixed with cells co-expressing glycoprotein S and the alpha peptide of β-Gal, and cell fusion leads to alpha-omega complementation. Fusion is stopped by lysing the cells and, after addition of the substrate (®The Tropix Galacto-Star™ chemiluminescent reporter assay system, Applied Biosystem), luminescence is quantified on a Tecan M1000PRO microplate reader.

**Cell toxicity assay.** HEK293T or Vero cells were incubated with the indicated concentration of the peptides or vehicle (dimethyl sulfoxide) at 37 °C. Cell viability was determined after 24h using the Vybrant MTT Cell proliferation Assay Kit according to the manufacturer’s guidelines. The absorbance was read at 540 nm using Tecan M1000PRO microplate reader. HAE cultures were incubated at 37°C in the presence or absence of 1, 10, or 100 μM concentrations of the peptide, and peptide was added to the feeding medium every 2 days for 7 days. Cell viability was determined on day 7 as above.
**Virus.** SARS-CoV-2 (isolate BetaCoV/Munich/BavPat1/2020; kindly provided by Prof. Dr. C. Drosten) was propagated to passage 3 on VeroE6 cells in OptiMEM I (1X) + GlutaMAX (Gibco), supplemented with penicillin (10,000 IU/mL, Lonza) and streptomycin (10,000 IU/mL, Lonza) at 37°C. VeroE6 cells were inoculated at a multiplicity of infection (MOI) of 0.01. Supernatant was harvested 72 hours post inoculation (HPI), cleared by centrifugation and stored at -80°C. All live virus work was performed in a Class II Biosafety Cabinet under BSL-3 conditions at Erasmus MC.

**In vitro potency of HRC dimer-chol.** Potency of [SARS$_{HRC}$-PEG$_4$]$_2$-chol was determined in an *in vitro* live virus fusion assay. Original stocks and working dilutions for animal experiments were tested in triplicate in VeroE6 and VeroE6-TMPRSS2 cells at concentrations of 0.06 nM to 5 µM. Peptide was pre-incubated with the cells for 1 hr at 37°C. After pre-incubation, virus (600 TCID$_{50}$) was added. After 8 hrs at 37°C, cells were washed and fixed with 4% PFA for 20 min at room temperature (RT). Plates were submerged in 70% ethanol and stained in a BSL-2 laboratory. In short, cells were washed with PBS and blocked with 10% normal goat serum (NGS) for 30 min at RT. Primary mouse-anti-SARS-CoV nucleocapsid antibody (1:1000, Biorad) was incubated for 1 hr at RT in 10% normal goat serum (NGS). After washing, secondary goat-anti-mouse IgG/FITC antibody (1:1000, Invitrogen) was incubated for 45 min at RT in 10% NGS. Fluorescent spots were visualized with an Amersham Typhoon Biomolecular Imager (GE Healthcare) and counted with ImageQuant TL 7.0 software (GE Healthcare).

**Ferret transmission experiment.** All animal handlings were performed under anaesthesia with a mixture of ketamine/medetomidine (10mg/kg and 0.05mg/kg, respectively) antagonized by atipamezole (0.25 mg/kg). Three donor ferrets were inoculated intranasally with $5.4 \times 10^5$ TCID$_{50}$ of SARS-CoV-2 in 450µl (225µl instilled dropwise in each nostril) and were housed together in a negatively pressurized
HEPA-filtered ABSL-3 isolator. This was considered the start of the experiment (0 days post inoculation, DPI). At the same time, twelve direct contact ferrets were divided over three other isolators. Ferrets were either mock-treated (vehicle, 2%DMSO in distilled water) or treated with [SARS$_{HRC}$PEG$_4$]$_2$-chol on 1-4 DPI. The peptide was inoculated intranasally in 450µl (225µl instilled dropwise in each nostril), HRC dimer-chol treated ferrets received a peptide dose of ~2.7 mg/kg. Leftover batches were stored at -80°C for later use in in vitro potency assays. At 2 DPI, six hours after the second treatment, one donor ferret was placed in the same isolators as two mock-treated and two peptide-treated ferrets, in three separate isolators (Fig. 3a). Each isolator now contained five ferrets, the donor ferret, the mock-treated recipient ferrets and the [SARS$_{HRC}$PEG$_4$]$_2$-chol-treated recipient ferrets. At 3 DPI, 18 hours after onset of co-housing, the animals received a third mock or peptide treatment, Six hours later, i.e. 24 hours after the start of the co-housing, the donor animals were moved back to their original isolator and the mock-treated and peptide-treated ferrets were housed in two groups of six animals in clean isolators.

Throat and nose swabs were collected from the animals on 0, 1, 2, 3, 4, 5, 6, 7, 14 and 21 DPI. Samples were always obtained prior to dosing with mock or peptide. Swabs were stored at -80°C in virus transport medium (Minimum Essential Medium Eagle with Hank's BSS (Lonza), 5 g L$^{-1}$ lactalbumine enzymatic hydrolysate, 10% glycerol (Sigma-Aldrich), 200 U/ml of penicillin, 200 mg/ml of streptomycin, 100 U/ml of polymyxin B sulfate (Sigma-Aldrich), and 250 mg/ml of gentamicin (Life Technologies)). Blood samples were obtained from ferrets on 0, 7, 14 and 21 DPI by vena cava puncture. Blood was collected in serum-separating tubes (Greiner), processed, heat-inactivated and sera were stored at -80°C. The study was stopped at 21 DPI. All animal experiments were performed in class III isolators in a negatively pressurized ABSL3 facility, all handlings were performed under general anaesthesia.

**RNA isolation and RT-qPCR on throat and nose swabs.** Sixty ul sample (virus transport medium in which swabs are stored) was added to 90 ul of MagNA Pure 96 External Lysis Buffer (Roche). A known
concentration of phocine distemper virus (PDV) was added to the sample as internal control for the RNA extraction (5). The 150 ul of sample/lysis buffer was added to a well of a 96-well plate containing 50 ul of magnetic beads (AMPure XP, Beckman Coulter). After thorough mixing, the plate was incubated for 15 min at room temperature. The plate was then placed on a magnetic block (DynaMag™-96 Side Skirted Magnet (ThermoFisher Scientific)) and incubated for 3 min to allow the displacement of the beads towards the side of the magnet. Supernatants were carefully removed and beads were washed three times for 30 sec at room temperature with 200 ul/well of 70% ethanol. After the last wash, a 20 ul multi-channel pipet was used to remove residual ethanol. Plates were air-dried for 2 min at room temperature. Plates were removed from the magnetic block and 50ul of PCR grade water was added to each well and mixed. Plates were incubated for 5 min at room temperature and then placed back on the magnetic block for 2 min to allow separation of the beads. Supernatants were pipetted in a new plate and RNA was stored at -80°C. The RNA was directly used for RTqPCR using primers and probes targeting the E gene of SARS-CoV-2 as previously described (6).

**Virus neutralization of ferret sera.** Seroconversion of ferrets was tested with ferret sera from 0, 7, 14 and 21 DPI. Duplicates of ferret sera were incubated with 100 TCID$_{50}$ of virus in a 2-fold dilution series starting at a concentration of 1:8 for 1 hr at 37°C. Virus-sera mix was added to VeroE6 cells and incubated for 5 days at 37°C. Cytopathic effect was used as readout to determine the minimal serum concentration required to inhibit CPE formation.
Figure S1. Specificity of SARS-CoV-2 inhibition by [SARS-CoV-2-HRC-PEG$_4$]-chol. A lipopeptide based on the human parainfluenza virus type 3 (HPIV3) F protein HRC domain, used as a negative control, did not inhibit fusion at any concentration tested.
Figure S2. *Ex vivo* cytotoxicity assessment. An MTT assay was used to determine the toxicity of the [SARS-CoV-2-HRC-peg₄]-chol in human airway epithelium (HAE). No toxicity was observed for the peptide at the concentrations of 1 and 10 µM. Toxicity was minimal (<20%) at the highest concentration tested (100 µM).
Figure S3: Potency of peptide stocks used in vivo. The potency of peptide dilutions used on 1-4 DPI in the in vivo experiments was confirmed with a live virus infection assay. The percentage infection events is shown on (A) VeroE6 and (B) VeroE6-TMPRSS with increasing concentrations of [SARS-CoV-2-HRC-peg₄]₂-chol (red) or mock (blue). Inhibitory concentrations 50% and 90% are indicated (dotted lines). Data are means ± standard error of the mean (SEM) from one experiment.
Figure S4. SARS-CoV-2-infected ferrets do not lose weight. Body weights of all ferrets remained stable over the time of the experiment. Donor animals shown in grey, mock-treated animals in red, peptide-treated animals in green. Symbols correspond to individual animals and are consistent throughout figures.
Figure S5. Identity of the conjugates was verified by MALDI-TOF MS. (A) MALDI of SARS\textsubscript{HRC}-PEG\textsubscript{4}-chol. Theoretical: 5170.8 Da; observed 5170.1 Da. (B) MALDI of [SARS\textsubscript{HRC}-PEG\textsubscript{4}]\textsubscript{2}-chol. Theoretical m/z: 10,335.4 Da; observed 10,339.10 Da. (C) MALDI of [SARS\textsubscript{HRC}]-PEG\textsubscript{11}. Theoretical m/z: 9841.0 Da; observed m/z: 9,839.40 Da.
References

1. T. N. Figueira et al., In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence. *J Virol* 91, (2017).
2. A. Z. Mykytyn et al., The SARS-CoV-2 multibasic cleavage site facilitates early serine protease-mediated entry into organoid-derived human airway cells. *bioRxiv*, 2020.2009.2007.286120 (2020).
3. V. K. Outlaw et al., Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. *mBio* 11, (2020).
4. M. Porotto et al., Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. *PLoS Pathog* 6, e1001168 (2010).
5. G. J. van Doornum, M. Schutten, J. Voermans, G. J. Guldemeester, H. G. Niesters, Development and implementation of real-time nucleic acid amplification for the detection of enterovirus infections in comparison to rapid culture of various clinical specimens. *J Med Virol* 79, 1868-1876 (2007).
6. V. M. Corman et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 25, (2020).